遗传性假性胆碱酯酶缺乏与琥珀胆碱:历史视角、治疗意义与未来考量
综述阐述琥珀胆碱经血浆假性胆碱酯酶水解,BCHE基因变异致酶活性降低或缺失者易发生神经肌肉阻滞延长。尽管该药物/基因关联发现较早,临床实施BCHE基因检测仍不普遍;文章汇总相关文献并讨论预先行BCHE基因检测以预防琥珀胆碱所致长时间麻痹、呼吸暂停及创伤后应激等后果。
要点
- 琥珀胆碱经血浆假性胆碱酯酶水解,BCHE变异者可致阻滞延长。
- 该关联为最早发现的药物基因组学关联之一,但临床实施仍不普遍。
- 预先行BCHE基因检测可能预防琥珀胆碱所致长时间麻痹。
核心结论
- BCHE基因变异导致假性胆碱酯酶活性降低或缺失者,使用琥珀胆碱后神经肌肉阻滞延长风险增加。
- 预先行BCHE基因检测可能预防琥珀胆碱所致长时间麻痹及其严重躯体与心理后果。
研究设计与样本
- 综述,汇总并批判性审视已发表文献中BCHE基因检测与琥珀胆碱反应相关的内容。
主要发现
- 琥珀胆碱在血浆中由假性胆碱酯酶(丁酰胆碱酯酶)水解为无活性代谢物。
- 携带BCHE基因变异致酶活性降低或无活性者,使用琥珀胆碱后神经肌肉阻滞延长风险增加。
- 琥珀胆碱/BCHE为最早发现的药物基因组学药物/基因关联之一,但当今临床实施仍属例外而非惯例。
- 琥珀胆碱所致长时间麻痹可造成呼吸暂停等严重躯体后果及创伤后应激等心理后果。
临床怎么用
- 对使用琥珀胆碱的患者,应关注BCHE基因变异所致假性胆碱酯酶缺乏风险。
- 可考虑预先行BCHE基因检测以预防琥珀胆碱所致长时间神经肌肉阻滞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Succinylcholine, a commonly used neuromuscular blocker, is hydrolyzed by the pseudocholinesterase (also known as butyrylcholinesterase) enzyme in the plasma to inactive metabolites. Individuals who have inherited genetic variants in the BCHE gene that result in decreased or no pseudocholinesterase enzyme activity are at increased risk of prolonged neuromuscular blockade with succinylcholine. Although succinylcholine/BCHE is one of the earliest identified pharmacogenomic drug/gene associations, clinical implementation remains the exception rather than the norm today. This review will explore the historical roots of pseudocholinesterase deficiency, its therapeutic implications for succinylcholine use, and future considerations for BCHE genetic testing to minimize the occurrence of prolonged neuromuscular blockade that can cause serious physical (i.e., apnea) and psychological (i.e., post-traumatic stress) consequences for patients. A summary and critical examination of the published literature that includes BCHE genetic testing in relation to succinylcholine response is also provided. Prolonged paralysis with succinylcholine may be prevented with preemptive BCHE genetic testing.
引用
- Nguyen JQ, Paetznick C, Donnelly RS, et al. Hereditary Pseudocholinesterase Deficiency and Succinylcholine: Historical Perspective, Therapeutic Implications, and Future Considerations. Pharmacotherapy. 2025. PMID: 40778538. doi:10.1002/phar.70048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。